AKT1 and melanoma: The siRNA to RAF or AKT could be loaded in cationic nanoliposomes, and the siRNA-loaded nanoliposomes selectively target melanoma tumor cells as well as early melanocytic lesions, resulting in the prevention of melanoma metastasis [60].